Levulan ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
34	Neurofibromatosis	2

34. Neurofibromatosis

---

Clinical trials : 133 /  Drugs : 186 - (DrugBank : 67) / Drug target genes : 79 - Drug target pathways : 190

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02728388 (ClinicalTrials.gov)	August 2016	25/3/2016	Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II	Topical Photodynamic Therapy (PDT) With Levulan® Kerastick® for Benign Dermal Neurofibromas Phase II	NEUROFIBROMATOSIS 1	Drug: aminolevulinic acid	Harry T Whelan, MD	NULL	Recruiting	14 Years	30 Years	All	30	Phase 2	United States
2	NCT01682811 (ClinicalTrials.gov)	March 12, 2012	5/9/2012	Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)	Photodynamic Therapy for Benign Dermal Neurofibromas Using Levulan Kerastick For Topical Solution, Plus Illumination With Red Light	Neurofibromatoses	Drug: Part 1 Levulan injection;Drug: Part 1 Levulan surface application;Drug: Part 1 Levulan surface application twice;Drug: Part 1 Levulan surface application twice with microneedling;Drug: Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1;Drug: Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2;Drug: Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3	Harry T Whelan, MD	NULL	Completed	18 Years	90 Years	All	20	Phase 1	United States